Eisai launches Fycompa in UK
This article was originally published in Scrip
Eisai has launched its epilepsy drug Fycompa (perampanel) in the UK at a competitive flat rate NHS list price of £5.00 per patient per day, regardless of dose.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.